Ezetimibe

CHEMBL1138 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
409.4 g/mol
LogP
4.0
Phase
4

This oral medication reduces cholesterol levels by blocking its absorption from food in the small intestine, lowering the amount of cholesterol that reaches the liver and bloodstream. It is often used alongside a statin for greater cholesterol reduction.

分子量

409.4000 g/mol

LogP

4.00

TPSA

60.80 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1

InChI

InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1

Molecular Formula

C24H21F2NO3

HBD / HBA

2 / 5

可旋转键数

6

重原子数

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This oral medication reduces cholesterol levels by blocking its absorption from food in the small intestine, lowering the amount of cholesterol that reaches the liver and bloodstream. It is often used alongside a statin for greater cholesterol reduction.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Ezetimibe is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1138. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 150311. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.